Bicycle therapeutics announces $555 million private placement equity financing

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that the company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 25,933,706 american depositary shares (“adss”), each representing one ordinary share, and in lieu.
BCYC Ratings Summary
BCYC Quant Ranking